BioLineRx Ltd. filed a Form D with the Securities and Exchange Commission on 2026-09-09.
BioLineRx Ltd. filed a Form D notice of an exempt securities offering with the SEC on September 9, 2026. The filing reports $3.75M sold. Its industry group is Biotechnology. It names Philip Serlin (Chief Executive Officer), Mali Zeevi (Chief Financial Officer), Ella Sorani (Chief Development Officer) (SEC Form D, September 9, 2026).
Sell to companies like BioLineRx Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-09 · the record
Pitching, partnering or investing alongside them? See who really runs and owns BioLineRx Ltd.
Free to see. No signup.
More on the people and the money behind BioLineRx Ltd., from the filings we hold.
Biotechnology raises by companies based in Israel, filed within 90 days of this one, largest first.
Get an email when BioLineRx Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when BioLineRx Ltd. raises, hires or launches. No email unless you switch it on.
Watch BioLineRx Ltd. →Get the full cited report on BioLineRx Ltd.
What the filing shows about BioLineRx Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioLineRx Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Trailing twelve months. 771 filings in Biotechnology, totalled by week. The dot is this raise, $3.75M, on the same scale — one filing against the whole group's total, so it sits low by construction.
The Company intends to use the net proceeds or research and development activities and working capital and general corporate purposes.
By form type: 6-K ×397 · 424B5 ×31 · SC 13G/A ×23 · SC 13G ×19 · CT ORDER ×18 · 20-F ×15 · EFFECT ×15 · 3 ×10, and others.
| Form | Filed | On EDGAR |
|---|---|---|
| 6-K | 2026-09-10 | open |
| D | 2026-09-09 | open |
| 424B5 | 2026-08-31 | open |
| 6-K | 2026-08-31 | open |
| 6-K | 2026-08-31 | open |
| 6-K | 2026-08-28 | open |
| 6-K | 2026-08-18 | open |
| 6-K | 2026-07-08 | open |
| 6-K | 2026-05-27 | open |
| 6-K | 2026-05-22 | open |
What the filing shows about BioLineRx Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on BioLineRx Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on BioLineRx Ltd. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 10 most recent of 612 filings on CIK 0001498403, filed as BioLineRx Ltd.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in L3. Full history on sec.gov.
On the filing as: Executive Officer.
Philip Serlin is named as Chief Executive Officer on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
On the filing as: Executive Officer.
Mali Zeevi is named as Chief Financial Officer on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
On the filing as: Executive Officer.
Ella Sorani is named as Chief Development Officer on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Aharon Schwartz is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Rami Dar is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
BJ Bormann is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Raphael Hofstein is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Avraham Molcho is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Sandra Panem is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Shaoyu Yan is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
Gal Cohen is named as Director on the Form D that BioLineRx Ltd. filed with the SEC on 9 September 2026, one of 11 people that filing names.
11 people named on the filing — 3 holding an executive role and 8 as directors only.
Named as of the 2026-09-09 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist BioLineRx Ltd.You get an alert in MentionFox the next time this company shows up.
If you're behind BioLineRx Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for BioLineRx Ltd.. With no account yet, you sign up free and land on the result.
On these lists: Outside the US raises, week of 2026-09-07 · Biotech raises, week of 2026-09-07
https://mentionfox.com/funding/biolinerx-ltd-form-d-004469